title: Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do.
authors.forename: Paolo
authors.initials: P
authors.lastname: Manzoni
authors.forename: Ugo
authors.initials: U
authors.lastname: Sala
authors.forename: Giovanna
authors.initials: G
authors.lastname: Gomirato
authors.forename: Alessandra
authors.initials: A
authors.lastname: Coscia
authors.forename: Claudio
authors.initials: C
authors.lastname: Fabris
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000097:blood; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069455:Palivizumab